Metabolic associated fatty liver disease and sarcopenia additively increase mortality: a real-world study.

Sarcopenia in individuals with MAFLD portends increased mortality and significant liver fibrosis. Novel therapeutic strategies targeting at increasing skeletal muscle mass should be explored for patients with MAFLD.